Academia can be an excellent source of novel drug targets and new technologies that can enhance medicinal discovery. Indeed, academic inventors or founders contributed to more than one-quarter of all medicines approved from 2001 through 2019.
Yet many sponsored research collaborations that hope to tap into academia fail. Academic-industry partnerships present a unique set of challenges that require thoughtful setup and dedicated execution from both the company and academic institution.
While there are many important details of a successful biopharma-academia collaboration, I see three key aspects that biopharma companies should take into account in order to increase the probability of a successful endeavor:
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
